Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O75419
UPID:
CDC45_HUMAN
Alternative names:
PORC-PI-1
Alternative UPACC:
O75419; B4DDB4; B4DDU3; E9PDH7; O60856; Q20WK8; Q6UW54; Q9UP68
Background:
Cell division control protein 45 homolog (CDC45), also known as PORC-PI-1, is pivotal in chromosomal DNA replication. As a core component of the CDC45-MCM-GINS (CMG) helicase, it plays a crucial role in unwinding template DNA, serving as the foundation around which the replisome is constructed.
Therapeutic significance:
CDC45's involvement in Meier-Gorlin syndrome 7, characterized by growth retardation and skeletal anomalies, underscores its potential as a target for therapeutic intervention. Understanding the role of CDC45 could open doors to potential therapeutic strategies.